A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin.

Autor: Meconi F; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Provenzano I; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Nasso D; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Mariotti B; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Pupo L; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Secchi R; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Cerretti R; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Lucia A; Anatomic Pathology Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy., Arcese W; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Cantonetti M; Department of Biomedicine and Prevention University Tor Vergata Rome Italy.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2020 May 05; Vol. 8 (8), pp. 1353-1356. Date of Electronic Publication: 2020 May 05 (Print Publication: 2020).
DOI: 10.1002/ccr3.2898
Abstrakt: Occasionally, non-Hodgkin lymphomas (NHL) occur simultaneously or subsequently to Hodgkin disease. We report on a case of a woman with Hodgkin lymphoma treated with ABVD, who developed 4 years later T-cell NHL with both nodal and extranodal involvement. Brentuximab vedotin could be an effective choice in treating metachronous T-cell NHL.
Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper.
(© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje